Iovance Biotherapeutics shares surged 31.5% to $14.45 after the company raised its full-year 2026 revenue guidance to $410-$420 million from $350-$370 million. The stock is expected to report quarterly revenues of $106.85 million (up 58.4% year-over-year) with a loss of $0.12 per share. However, analysts note that without recent earnings estimate revisions, the stock's momentum may not sustain, and the company carries a Zacks Rank #3 (Hold) rating.

As prostate cancer incidence rises with advanced-stage diagnoses increasing, four pharmaceutical companies are advancing treatments. Pfizer and Novartis, with established prostate cancer franchises, await FDA decisions on label expansions for Talzenna/Xtandi and Pluvicto respectively. Candel and Janux, earlier-stage developers, are preparing regulatory filings and advancing clinical programs in this growing market.

Janux Therapeutics announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb worth up to $800 million. Janux will receive $50 million in upfront and near-term milestone payments, with Bristol Myers Squibb handling subsequent development and commercialization of novel immunotherapies for solid tumors. The deal validates Janux's tumor-activated platform technology.

Janux Therapeutics stock rose nearly 12% after an analyst raised his price target, though he maintained a 'sector perform' rating. The company also launched a $300 million secondary stock offering to advance its cancer treatment pipeline.

Throughout the last three months, 9 analysts have evaluated Janux Therapeutics (NASDAQ:JANX), offering a diverse set of opinions from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 3 1 0 0 Last 30D 0 0 1 0 0 1M Ago 1 2 0 0 0 2M Ago 1 0 0 0 0 3M Ago 3 1 0 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $68.22, a high estimate of $100.00, and a low estimate of $47.00. This current average has increased by 68.44% from the previous average price target of $40.50. Investigating Analyst Ratings: An Elaborate Study A comprehensive examination of how financial experts perceive Janux Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target George Farmer Scotiabank Announces Sector Perform $47.00 - Swayampakula Ramakanth HC Wainwright & Co. Raises Buy $63.00 $50.00 Josh Schimmer Cantor Fitzgerald Maintains Overweight $100.00 - Robert Driscoll Wedbush Raises Outperform $74.00 $53.00 Soumit Roy JonesTrading Announces Buy $70.00 - Kaveri Pohlman BTIG Announces Buy $62.00 - Josh Schimmer Cantor Fitzgerald Announces Overweight $100.00 - Geoff Meacham B of A Securities Raises Buy $48.00 $24.00 Swayampakula Ramakanth HC Wainwright & Co. Raises Buy $50.00 $35.00 Key Insights: Action ...Full story available on Benzinga.com

In the preceding three months, 9 analysts have released ratings for Janux Therapeutics (NASDAQ:JANX), presenting a wide array of perspectives from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 4 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 2 0 0 0 2M Ago 1 1 0 0 0 3M Ago 2 1 0 0 0 Analysts have set 12-month price targets for Janux Therapeutics, revealing an average target of $68.89, a high estimate of $100.00, and a low estimate of $48.00. Witnessing a positive shift, the current average has risen by 85.19% from the previous average price target of $37.20. Decoding Analyst Ratings: A Detailed Look The standing of Janux Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Swayampakula Ramakanth HC Wainwright & Co. Raises Buy $63.00 $50.00 Josh Schimmer Cantor Fitzgerald Maintains Overweight $100.00 - Robert Driscoll Wedbush Raises Outperform $74.00 $53.00 Soumit Roy JonesTrading Announces Buy $70.00 - Kaveri Pohlman BTIG Announces Buy $62.00 - Josh Schimmer Cantor Fitzgerald Announces Overweight $100.00 - Geoff Meacham B of A Securities Raises Buy $48.00 $24.00 Swayampakula Ramakanth HC Wainwright & Co. Raises Buy $50.00 $35.00 David Driscoll Wedbush Raises Outperform $53.00 $24.00 Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their ...Full story available on Benzinga.com

Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of -0.43% and 5.68%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Janux Therapeutics (JANX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

In the latest quarter, 6 analysts provided ratings for Janux Therapeutics (NASDAQ:JANX), showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 1 0 0 0 2M Ago 2 1 0 0 0 3M Ago 0 0 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $63.83, along with a high estimate of $100.00 and a low estimate of $48.00. Marking an increase of 130.68%, the current average surpasses the previous average price target of $27.67. Analyzing Analyst Ratings: A Detailed Breakdown A comprehensive examination of how financial experts perceive Janux Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Soumit Roy JonesTrading Announces Buy $70.00 - Kaveri Pohlman BTIG Announces Buy $62.00 - Josh Schimmer Cantor Fitzgerald Announces Overweight $100.00 - Geoff Meacham B of A Securities Raises Buy $48.00 $24.00 Swayampakula Ramakanth HC Wainwright & Co. Raises Buy $50.00 $35.00 David Driscoll Wedbush Raises Outperform $53.00 $24.00 Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether ...Full story available on Benzinga.com

Janux (JANX) stock surges after some reports claim that the company is exploring opportunities for a potential sale following buyout offers from big pharma companies.

If you are looking for stocks that are well positioned to maintain their recent uptrend, Janux Therapeutics (JANX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Janux's silence about a potential acquisition deal could be golden.